IMPLEMENTATION BRIEF
Understanding access issues for new therapies
This brief outlines several major barriers to patient access for novel cell and gene therapies. It also describes how providers, payers, and developers may overcome these barriers, with a focus on addressing these challenges for the new sickle cell disease (SCD) therapies, Casgevy and Lyfgenia.
Get the implementation brief
Recent news
NEWDIGS leaders named to Illinois SCD Advisory Council
Jul 02, 2024ISPOR 2024 panel recap: Will the Pediatric Rare Disease Pipeline Create a Financial Tsunami? Implications of a Monte Carlo Projection
May 21, 2024BioCentury OpEd: Biomedical Innovation Requires Health System Innovation
May 14, 2024Managing the Challenges of Paying for Gene Therapy: New ICER / NEWDIGS whitepaper
Apr 23, 2024Better Outcomes Tracking: A First Step In Improving Access To New Treatments
Apr 08, 2024Our mission is to improve health outcomes by accelerating appropriate, timely, and equitable patient access to biomedical products in ways that work for all stakeholders.
We design and catalyze solutions with an integrated systems view through complementary approaches of public-private partnerships (our consortium), sponsored research, custom education, and experiential action learning.
